McKesson Corporation (MCK), a prominent player in the biotech sector, is receiving increased attention from investors. Several investment groups have recently increased their holdings in MCK, indicative of its enduring attractiveness. Nonetheless, high-profile execs, notably EVP Lau Michele, are unloading their shares. Despite this, a wave of stakeholdings, such as that of HF Advisory Group LLC and Northstar Advisory Group, reinforces investor faith. Despite its record of performance, including
Q3 earnings that impressed Wall Street, some analysts flag potential overvaluation following a 58% rally over the last year. Meanwhile, Wall Street forecasts remain bullish, with Bank of America raising its target to $1,040, Barclays maintaining an optimistic outlook, and Deutsche Bank raising its price target despite plans for a spin-off. The firm's recent CFO transition and
biosimilar efforts are transforming its investment story.
McKesson's strong Q3 performance and successive
AI initiatives are widely speculated to have a possible reshaping effect on its risk-return profile. The company has also successfully completed the divestiture of its Norwegian operations, part of a larger strategic refocusing campaign.
Mckesson Corporation MCK News Analytics from Thu, 18 Sep 2025 07:00:00 GMT to Sat, 04 Apr 2026 12:31:23 GMT -
Rating 8
- Innovation 5
- Information 9
- Rumor -5
